ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

By afschroeder • February 12, 2026

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S. ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL. Blood Adv. 2026 Feb 11:bloodadvances.2021006479. doi: 10.1182/bloodadvances.2021006479. Epub ahead of print. PMID: 41670624.

Tags: Hematology/Oncology, Publications

Related Posts

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies

Shan NL, Balinda H, Dai J, Wang Y, Lin HK, Marczyk M, Espinoza Campos G, Umlauf S, McDermott MSJ, Colorado I, Lang SM, Surovtseva YV,[...]

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review

Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United[...]